By NovaMedSpa.com Editorial Team | January 31, 2026
Weight loss medication results vary dramatically from person to person, making it challenging to set realistic expectations before starting a program like MEDVi. We've analyzed patient testimonials, clinical data, and self-reported outcomes to give you an honest picture of what results you might achieve and the timeline you should expect.
For those new to MEDVi's telehealth platform, our complete overview explains how the program works and what's included in their GLP-1 offerings.
Understanding MEDVi's Published Results Claims
MEDVi markets several outcome statistics on their website that deserve context:
“6x more weight loss than exercise and diet alone”: This comparison aligns with clinical trial data for GLP-1 medications generally. In the STEP 1 trial for semaglutide, participants lost approximately 14.9% of body weight compared to 2.4% for the placebo group (who received diet and exercise counseling alone). That's roughly a 6:1 ratio.
“Average 18% body weight loss”: This figure appears to reference higher-dose or tirzepatide-specific outcomes. Semaglutide trials showed 14.9% average loss, while tirzepatide trials demonstrated up to 20-22% at maximum doses. The 18% figure likely represents a blended average across their patient population.
“93% kept weight off for good”: This claim requires careful interpretation. Weight maintenance after GLP-1 discontinuation is an industry-wide challenge—studies show significant weight regain when medications are stopped. The 93% figure likely refers to patients who remained on medication rather than those who maintained weight after stopping treatment.
Real Patient Outcome Data
We've aggregated results from verified patient reviews across multiple platforms. Here's what actual MEDVi users report:
Short-Term Results (1-3 Months): Most patients report 8-15 pounds lost in the first three months. One verified December 2025 review described losing 20 pounds (158 to 138 lbs) in two months on tirzepatide—results on the higher end of typical outcomes. The first month often shows the most dramatic appetite reduction, with patients describing much less “food noise” and fewer cravings.
Medium-Term Results (4-6 Months): Patients maintaining treatment typically report 15-20% total body weight reduction by month six. A 200-pound starting weight would translate to 30-40 pounds lost. Analysis of telehealth GLP-1 programs suggests these outcomes are consistent with broader industry data.
Long-Term Results (6-12+ Months): Weight loss typically continues but at a slower pace after the initial months. Patients report reaching plateaus that may require dose adjustments. One-year outcomes vary widely, with dedicated patients reporting 25-35% body weight reduction while others plateau at 15-20%.
Factors That Influence Results
Understanding why results vary helps set appropriate expectations:
Starting Weight: Patients with higher starting BMIs often see larger absolute weight loss but similar percentage reductions. A 300-pound person might lose 60 pounds (20%) while a 180-pound person loses 36 pounds (20%).
Medication Choice: Tirzepatide produces approximately 6-7% greater weight loss than semaglutide based on head-to-head trials. MEDVi patients choosing tirzepatide should expect enhanced results compared to semaglutide users.
Lifestyle Factors: GLP-1 medications work best when combined with reduced-calorie diets and increased physical activity. Clinical research confirms that lifestyle modifications noticeably amplify medication effects. Patients who treat the medication as a standalone solution typically see less impressive results.
Adherence: Consistent weekly dosing matters. Missed doses or irregular administration reduces effectiveness. MEDVi's monthly subscription model helps maintain adherence through regular medication delivery.
Genetics and Metabolism: Individual response to GLP-1 medications varies based on genetic factors that researchers are still working to understand. Some patients are “super responders” while others see modest results despite optimal adherence.
Timeline Expectations
Here's a realistic month-by-month breakdown of what most MEDVi patients experience:
Week 1-2: Appetite reduction begins, often dramatically. Most patients notice decreased hunger within the first week. Gastrointestinal side effects (nausea, constipation) are common as your body adjusts. Scale changes may be minimal as you're starting at low doses.
Week 3-4: Side effects typically begin stabilizing. Weight loss becomes more visible, usually 3-6 pounds by month end. Patients report easier portion control and reduced food fixation.
Month 2: Dose titration continues. Weight loss accelerates for most patients, with 1-2 pounds per week being typical. Food relationships begin shifting as appetite signals normalize.
Month 3-4: Many patients reach or approach maintenance dosing. Weight loss continues steadily. This is when patients often report the most significant improvements in energy and overall wellbeing.
Month 5-6: Some patients hit their first plateau. Dose adjustments or switching medications (semaglutide to tirzepatide) may restart progress. Most reach 15-20% total weight reduction by this point.
Month 7-12: Weight loss continues but typically slows. Focus shifts toward maintenance and sustainable lifestyle habits. Patients report stabilizing at their new weight if adherence continues.
What the Reviews Actually Say
Beyond aggregate statistics, individual stories provide context:
Success Stories: Multiple reviewers describe life-changing results—losing 50, 80, even 100+ pounds over extended treatment periods. Patients report improved energy, better sleep, reduced joint pain, and improved blood work markers. The emotional impact appears significant, with reviewers frequently mentioning restored confidence.
Mixed Results: Not every experience is uniformly positive. Some patients report modest weight loss despite adherence, while others describe persistent side effects that made continuation difficult. A few reviewers mention seeing better results from competing platforms or local providers.
Factors in Negative Reviews: Most negative outcome reviews involve shipping delays causing treatment gaps, pricing confusion affecting consistent treatment, or unrealistic expectations about speed of results. Medication effectiveness itself is rarely questioned—issues tend to be operational rather than clinical.
Beyond the Scale: Other Health Improvements
Weight loss medications produce benefits beyond the scale number:
Metabolic Improvements: Patients frequently report improved blood sugar levels, better cholesterol profiles, and reduced blood pressure. Some reviewers describe being taken off previous medications as their metabolic health improved.
Physical Wellbeing: Reduced joint pain, improved mobility, better sleep quality, and increased energy levels appear consistently in patient testimonials. Research on GLP-1 outcomes supports these secondary benefits.
Psychological Benefits: Patients describe reduced food obsession, easier relationship with eating, and improved body image. The mental relief from constant hunger and craving management appears as meaningful as physical weight loss for many users.
Setting Realistic Expectations
Based on our analysis, here's what constitutes realistic expectations for MEDVi patients:
Realistic: Losing 15-20% of starting body weight over 6-12 months with consistent adherence and lifestyle modifications. Experiencing initial gastrointestinal side effects that improve over time. Needing ongoing treatment to maintain results.
Optimistic but Possible: Losing 20-25%+ of body weight with tirzepatide at higher doses. Minimal side effects throughout treatment. Maintaining weight with reduced medication doses after reaching goals.
Unrealistic: Losing weight without any dietary changes or increased activity. Achieving goal weight in the first month or two. Maintaining weight loss indefinitely after stopping medication. Zero side effects during the adjustment period.
The Bottom Line on MEDVi Results
MEDVi's GLP-1 programs produce results consistent with what clinical trials predict for semaglutide and tirzepatide. Most patients who maintain consistent treatment see meaningful weight loss that improves health markers and quality of life.
Success depends heavily on realistic expectations, consistent adherence, and willingness to combine medication with lifestyle modifications. The medication provides a powerful tool, but it works best when viewed as part of an overall approach rather than a magic solution.
Individual results vary dramatically. This analysis is informational and doesn't guarantee specific outcomes. Consult with a qualified healthcare provider to determine if GLP-1 therapy is appropriate for your situation.
Frequently Asked Questions About MEDVi Weight Loss Results
What's the average weight loss in the first month with MEDVi? Most patients report 4-8 pounds in the first month, though this varies based on starting weight and individual metabolism. Don't be discouraged if your first month shows less dramatic results—weight loss typically accelerates after reaching therapeutic doses.
Will I regain weight if I stop MEDVi treatment? Research shows that most patients regain some weight after discontinuing GLP-1 medications. This doesn't mean the treatment failed—it means these medications work best as ongoing therapy rather than short-term fixes. Many patients continue treatment at maintenance doses long-term.
How does exercise affect results while on MEDVi medications? Exercise amplifies weight loss results and helps preserve muscle mass during rapid weight loss. Patients who combine MEDVi treatment with regular physical activity typically see better outcomes and report improved energy levels compared to medication-only approaches.
What should I eat while taking GLP-1 medications? The reduced appetite from GLP-1s makes it easier to follow a calorie-controlled diet naturally. Focus on protein to preserve muscle mass, along with vegetables and whole foods. Many patients find they can't tolerate greasy or heavy foods as well while on these medications.
Can MEDVi help me lose the last 10-15 pounds? GLP-1 medications work better for patients with higher BMIs. If you're already at a relatively healthy weight and just want to lose a small amount, results may be less dramatic. These medications are designed for clinically meaningful weight loss in patients with obesity or weight-related health conditions.